AngioDynamics (ANGO) Tops Q1 EPS by 7c, Beats on Revenue; Offers F27 Revenue Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/3/2026

1. AAPL
2. PLTR
3. DOX
4. VRTX
5. CHKP
6. CRWD
7. ON
8. INSP
9. CVI
10. HNGE

Go back to AngioDynamics (ANGO) Tops Q1 EPS by 7c, Beats on Revenue; Offers F27 Revenue Guidance

AngioDynamics Reports Fiscal Year 2027 First Quarter Financial Results; Continued Execution Drives Med Tech Growth and Profitability

October 8, 2026 6:02 AM EDT

Delivered its eighth consecutive quarter of double-digit Med Tech segment growth and positive adjusted EBITDA

LATHAM, N.Y.--(BUSINESS WIRE)-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the bodys vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the first quarter of fiscal year 2027, which ended August 31, 2026.

Fiscal Year 2027 First Quarter Financial Highlights

... More